NeuroSense Therapeutics (NRSN) investor relations material

Corporate highlights and leadership

• Achieved significant positive results in a placebo-controlled phase 2b study for ALS, with PrimeC slowing disease progression by 33% over 18 months (p=0.007) compared to placebo.

• Patent protection for PrimeC extends until 2042, covering formulation, method, and combination.

• Expedited regulatory pathway with orphan drug designation and 505(b)2 status.

• Leadership team includes experienced executives and a renowned scientific advisory board with global ALS experts.

Disease focus and market opportunity

• Focused on neurodegenerative diseases with high unmet need, including ALS, Alzheimer's, and Parkinson's.

• Over 200,000 ALS patients worldwide, with >30,000 in US/Canada and >30,000 in Europe; ~5,000 new US cases annually.

• ALS market opportunity exceeds $1B annually, with ALS drug prices around $160,000/year and projected 24% patient growth by 2040 in US/EU.

PrimeC mechanism and clinical data

• PrimeC is a patented, fixed-dose combination of celecoxib and ciprofloxacin, with synchronized release for multi-targeted action against inflammation, iron accumulation, and miRNA dysregulation.

• Demonstrated superior neuronal survival in ALS models and reduced neuroinflammation and TDP-43 levels in clinical studies.

• Phase 2b PARADIGM trial: randomized, placebo-controlled, double-blind, with well-balanced baseline characteristics.